Wave Life Sciences’ stock soars 51% after biotech posts positive data from Duchenne muscular-dystrophy trial
Biotech reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder Duchenne muscular dystrophy.
Biotech reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder Duchenne muscular dystrophy.
